Corrects paragraph 3 to say the drug showed reduction of 7.9 mmHg, not 11.7 mmHg, in mid-stage study
March 10 (Reuters) - Mineralys Therapeutics MLYS.O said on Monday its experimental drug met the main goal of lowering blood pressure in patients with uncontrolled or resistant hypertension in late- and mid- stage trials, sending its shares up about 43% before the bell.
In the late-stage study, the treatment called lorundrostat showed a placebo-adjusted reduction in systolic blood pressure by 9.1 mmHg (millimeters of mercury) at week six. The benefit was sustained through week 12, with a further reduction to 11.7 mmHg.
The drug also reduced systolic blood pressure by 7.9 mmHg in a mid-stage trial when compared to a placebo, the company said.
Lorundrostat inhibits the production of aldosterone, a hormone that can contribute to high blood pressure.
(Reporting by Kamal Choudhury in Bengaluru; Editing by Sriraj Kalluvila)
((Kamal.Choudhury@thomsonreuters.com;))
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。